Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | PGD | P52209 | 3/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | TPI1 | P60174 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038892 | 0.98 | LPAR3 (0.40) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL3425549 | 0.81 | LPAR3 (0.41) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL27897702 | 0.80 | LPAR3 (0.42) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL202466 | 0.78 | LPAR3 (0.43) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL27399517 | 0.77 | LPAR3 (0.39) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL11675767 | 0.76 | LPAR3 (0.41) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL27190160 | 0.76 | LPAR3 (0.41) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL11299607 | 0.76 | LPAR3 (0.38) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL2048486 | 0.74 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL31506206 | 0.74 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101568-B2 | Methods and compositions for treating solid tumors | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1185249-B1 | Use of a biodegradable polymer | GUILFORD PHARM INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20030203033-A1 | Methods and compositions for treating solid tumors | EISAI INC. | 2003-10-30 | — | — | US | disclosed |
| US-6537585-B1 | Methods and compositions for treating solid tumors | GUILFORD PHARMACEUTICALS, INC. | 2003-03-25 | — | — | US | disclosed |
| EP-1185249-A2 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000057852-A2 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS | GUILFORD PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203033-A1 | Methods and compositions for treating solid tumors | MKI67, TP53, POLI | LPAR3 1184/4885LPAR2 1317/4885LPAR1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.